CYP24A1 and cancer: These results are in line with a multiethnic meta-analysis with 1419 cases in 5 studies in 4 types of cancer (head and neck, lung, breast, and colorectal), which evaluated the impact of 5 SNPs with some role in cancer survival (rs2296241, rs6068816, rs2762934, rs4809957, rs6013897) on survival, finding that the polymorphisms of CYP24A1 were positively associated with a worse prognosis (HR = 1.42; 95% CI = 1.16–1.68; I2 = 0.0) [66].